Liposome-Encapsulated Prednisolone Phosphate Inhibits Growth of Established Tumors in Mice  by Schiffelers, Raymond M. et al.
Liposome-Encapsulated Prednisolone Phosphate Inhibits
Growth of Established Tumors in Mice1
Raymond M. Schiffelers*, Josbert M. Metselaar*, Marcel H. A. M. Fens*, Adrie¨nne P. C. A. Janssen*,
Grietje Molema y and Gert Storm*
*Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht,
The Netherlands; yDepartment of Pathology and Laboratory Medicine, Groningen University Institute for
Drug Exploration (GUIDE), Groningen, The Netherlands
Abstract
Glucocorticoids can inhibit solid tumor growth possi-
bly due to an inhibitory effect on angiogenesis. The
antitumor effects of the free drugs have only been
observed using treatment schedules based on high
and frequent dosing for prolonged periods of time.
As long-circulating liposomes accumulate at sites of
malignancy, we investigated the tumor-inhibiting po-
tential of liposome-encapsulated prednisolone phos-
phate. Liposomal prednisolone phosphate could
inhibit tumor growth dose-dependently, with 80% to
90% tumor growth inhibition of subcutaneous B16.F10
melanoma and C26 colon carcinoma murine tumor
models at 20 mg/kg by single or weekly doses. Pred-
nisolone phosphate in the free form was completely
ineffective at this low-frequency treatment schedule,
even when administered at a dose of 50 mg/kg. In vitro
studies did not show an inhibitory effect of predniso-
lone (phosphate) on tumor cell, nor on endothelial cell
proliferation. Histologic evaluation revealed that lipo-
somal prednisolone phosphate–treated tumors con-
tained a center with areas of picnotic/necrotic cells,
which were not apparent in untreated tumors or tumors
treated with the free drug. In conclusion, the present
study shows potent antitumor effects of liposomal
formulations of glucocorticoids in a low dose and low-
frequency schedule, offering promise for liposomal
glucocorticoids as novel antitumor agents.
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Introduction
Glucocorticoids have a wide spectrum of activities on cell
trafficking, cell–cell interactions, and cell communication,
leading to pronounced anti-inflammatory and immunosup-
pressive effects. Glucocorticoids exert their effects by dif-
fusion through the cell membrane and binding to their
cytosolic receptors. Subsequently, these receptors become
activated and translocate to the nucleus where they directly
modulate DNA transcription of a variety of genes. In addi-
tion, glucocorticoid receptors may directly or indirectly an-
tagonize the activity of several transcription factors, most
notably nuclear factor-nB [1,2]. At high concentrations, gluco-
corticoids also exert rapid nongenomic effects on cells by
interacting nonspecifically with cell membranes, or specifically
with membrane-bound glucocorticoid receptors [3].
In tumor therapy, glucocorticoids have been used for their
anti-inflammatory and antiemetic effects, and in the treatment
of hematologic malignancies based on their efficient cytolytic
activity on cells of lymphoid origin [4]. Reports in the last two
decades demonstrated that glucocorticoids could also inhibit
solid tumor growth in experimental animal models [5–8].
However, these preclinical studies further show that high and
frequent dosing of glucocorticoids is a prerequisite to obtain
antitumor effects. In mice, doses of 100 to 200 mg/kg per day
need to be administered for prolonged periods of time to obtain
significant tumor growth inhibition [5–8]. These doses resulted
in considerable morbidity and mortality as a result of severe
immune suppression [6,7].
Targeted delivery of glucocorticoids to tumor tissues could
be an attractive strategy to increase intratumoral drug concen-
trations, thereby reducing the overall dose and hence decreas-
ing the likelihood of side effects [9]. We investigated the ability
of long-circulating liposomes to deliver glucocorticoids selec-
tively to tumor tissues. These liposomes have previously been
shown to accumulate at sites of malignancy as a result of the
enhanced permeability of the tumor vasculature compared to
the healthy endothelium [10]. In the present study, antitumor
activity of liposomal prednisolone phosphate was investigated
in subcutaneous C26 colon carcinoma and B16.F10 mela-
noma models, and compared to the antitumor activity of free
prednisolone phosphate in different dosing schemes. In addi-
tion, to evaluate the importance of targeted delivery, effects
of short-circulating liposomes, which predominantly home to
the spleen, were compared to that of tumor-targeted long-
circulating liposomes [10]. Finally, to establish the possible
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mechanisms of antitumor activity, histologic analyses of
tumors were performed, focusing on neovascularization
pattern in relation to tumor cell morphology.
Materials and Methods
Liposome Preparation
Long-circulating liposomes were prepared as described
previously [11]. In brief, appropriate amounts of dipalmitoyl-
phosphatidylcholine (LipoidGmbH,Ludwigshafen,Germany),
cholesterol (Sigma, St. Louis, MO), and poly(ethylene
glycol) 2000-distearoylphosphatidylethanolamine (Lipoid
GmbH), in a molar ratio of 1.85:1.0:0.15, respectively, were
dissolved in chloroform:methanol (2:1 vol/vol) in a round-
bottom flask. A lipid film was made under reduced pressure
on a rotary evaporator and dried under a stream of nitrogen.
Liposomes were formed by addition of an aqueous solution
of 100 mg/ml prednisolone phosphate disodium salt (Bufa,
Uitgeest, The Netherlands). A water-soluble phosphate de-
rivative of prednisolone was used to ensure stable encapsu-
lation in the liposomes as previous experiments showed
that unmodified prednisolone, although showing high initial
encapsulation efficiency, was rapidly lost upon intravenous
injection. For labeling of the liposomes with 0.5 mCi of 111In-
oxine (Mallinckrodt Medical, Petten, The Netherlands), the
lipid film was hydrated in 10 mM Hepes/135 mM NaCl buffer,
pH 7.4, containing 5 mM DTPA acting as the indium chelator
to a final lipid concentration of 10 mmol/ml, according to a
procedure described by Boerman et al. [12]. Liposome size
was reduced by multiple extrusion steps through polycarbon-
atemembranes (Nuclepore, Pleasanton, CA) with a final pore
size of 50 nm.
Short-circulating liposomes were prepared similarly; only
poly(ethylene glycol) 2000-distearoylphosphatidylethanol-
amine was replaced by egg phosphatidylglycerol (Lipoid
GmbH). For the preparation of short-circulating liposomes,
the poly(ethylene glycol)–conjugated lipid was replaced with
the negatively charged phospholipid phosphatidylglycerol.
The short-circulating liposomes were formed by the addition
of 10 mg/ml prednisolone phosphate in 10 mM Hepes/
135 mM NaCl buffer, pH 7.4, to the lipid film, and extrusion
took place through polycarbonate membranes of 400 nm.
The use of larger membrane pores for the short-circulating
liposomes reduces circulation time compared to the long-
circulating liposomes, and prevents efficient extravasation
at the target site [13,14]. Unencapsulated material for both
liposome types was removed by dialysis, with repeated
changes of buffer against 10 mM Hepes/135 mM NaCl
buffer, pH 7.4, at 4jC.
Mean particle size distribution of the liposomes was
determined by dynamic light scattering detected at an angle
of 90j to the laser beam on a Malvern 4700 System (Malvern
Instruments, Malvern, UK). In addition to the mean particle
size, the system reports a polydispersity index with a value
between 0 and 1. A polydispersity index of 1 indicates large
variations in particle size; a reported value of 0 means that
size variation is absent. Mean particle size was found to be
0.1 mm with a polydispersity value of around 0.1, whereas
the short-circulating liposomes had a mean particle size of
0.5 mm with a polydispersity value of around 0.3. Thus,
the polydispersity values indicate limited variation in parti-
cle size.
The f-potential of liposomes, as a measure for surface
charge, was determined using a zetasizer equipped with
PCS v1.35 software (Malvern Instruments). Liposomes were
prepared in 5% aqueous Hepes/NaCl buffer and the instru-
ment was calibrated with electrophoresis standard latex
particles. Long-circulating liposomes had a near neutral
surface charge, whereas short-circulating liposomes dis-
played a surface charge of 14 mV.
Phospholipid content was determined with a phosphate
assay, performed according to Rouser et al. [15], on the
organic phase after extraction of liposomal preparations with
chloroform. The aqueous phase after extraction was used for
determining the prednisolone phosphate content by high-
performance liquid chromatography as described previously
[11]. The detection limit for the high-performance liquid
chromatography setup was 20 ng/ml. The liposomal prepa-
ration contained f2 mg/ml prednisolone phosphate and
f60 mmol/ml phospholipid. Preparation methods based on
freeze–thawing of the liposomes before extrusion did not
improve encapsulation efficiency.
Colloidal gold-labeled SSL were prepared as described
previously [16]. Briefly, the lipid film was prepared as de-
scribed above. A 1.1% (wt/vol) aqueous solution of AuCl2
(Sigma-Aldrich Co., Zwijndrecht, The Netherlands) was four-
fold diluted with sodium citrate (28 mM)/potassium carbonate
(7 mM) buffer, filtered (0.2 mm), and used to hydrate the lipid
film at 4jC. Liposomes were prepared by multiple extrusion.
The resulting yellow liposome suspension was placed at
37jC, after which the color of the suspension turned purple.
Unencapsulated colloidal gold was removed by gel filtra-
tion of the liposomes over a Sephacryl SF S1000 column
(Pharmacia, Uppsala, Sweden) using Hepes/NaCl buffer as
the eluents. Resulting liposomes were 0.1 mm in size and
displayed a near-neutral surface charge.
Cells
B16.F10 murine melanoma and C26 murine colon carci-
noma cells were cultured at 37jC in a 5% CO2-containing
humidified atmosphere in DMEM medium (Gibco, Breda,
The Netherlands) supplemented with 10% (vol/vol) heat-
inactivated fetal calf serum (Gibco), 100 IU/ml penicillin,
100 mg/ml streptomycin, and 0.25 mg/ml amphotericin B
(Gibco). Human umbilical vein endothelial cells (HUVEC)
(Glycotech, Rockville, MD) were cultured in complete EGM en-
dothelial cell growth medium (Cambrex, East Rutherford, NJ).
Murine Tumor Models
Male C57Bl/6 and Balb/c mice (6–8 weeks of age) were
obtained from Charles River (Maastricht, The Netherlands),
and kept in standard housing with standard rodent chow and
water available ad libitum at a 12-hour light/dark cycle.
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Experiments were performed according to national regula-
tions and were approved by the local animal experiments
ethical committee. For tumor induction, 1  106 B16.F10
melanoma or C26 colon carcinoma cells were inoculated
subcutaneously in the flank of syngeneic C57Bl/6 or Balb/c
mice, respectively. B16.F10 tumors became palpable
around 7 days and C26 tumors around 10 days after tumor
cell inoculation.
Tissue Distribution of 111In-Labeled Liposomes in
Tumor-Bearing Mice
At a tumor volume of approximately 1 cm3, mice were
injected intravenously with 25 mmol/kg lipid (corresponding
to 30 106 cpm/mouse) of 111In-labeled liposomes. At 6 and
24 hours after injection, animals were killed by CO2 asphyx-
iation; a blood sample was taken; the tumor, lungs, liver,
spleen, and kidneys were dissected; the tissues were
weighed; and radioactivity was counted. Injection standards
were included to account for physical decay.
Tumor Growth Inhibition
Effect of dose Mice received a single intravenous injection
of an indicated dose of free prednisolone phosphate or lipo-
somal prednisolone phosphate at the time when the tumor
became palpable (tumor volumef20 mm3). At 7 days after
treatment, tumor size was measured and tumor volume
was calculated according to the formula: V = 0.52a2b, where
a is the smallest and b is the largest superficial diameter.
Dosing schedule Free prednisolone phosphate or liposo-
mal prednisolone phosphate was intravenously administered
at a dose of 20 mg/kg on days 1, 7, and 14, or by single
injection on day 7 or 14 after tumor cell inoculation. Tumor
size was measured regularly, and tumor volume was calcu-
lated as described above.
Analysis of Amount of Prednisolone in Tissues
At a tumor volume of approximately 1 cm3, mice were
injected intravenously with 20 mg/kg liposomal prednisolone
phosphate or free prednisolone phosphate. At 24 hours after
injection, animals were killed and tumor was dissected. The
tissues were weighed and homogenized. Two micrograms of
methylprednisolone was added as an internal standard, after
which prednisolone (phosphate) was extracted from the
tissue with ethylacetate at pH 2 and evaporated until dryness
under a nitrogen flow. Samples were reconstituted in etha-
nol:water 1:1 vol/vol and analyzed by high-performance
liquid chromatography as described previously [11]. Calibra-
tion curves were prepared by spiking control organs from
untreated mice with known amounts of prednisolone phos-
phate and prednisolone and analyzing these samples
according to the same procedure.
Effect of Prednisolone on Cell Proliferation In Vitro
To determine whether prednisolone (phosphate) had a
direct antiproliferative effect on cells, 5  103 cells/well
HUVEC, C26, and B16.F10 were plated in a 96-well plate.
Prednisolone (phosphate) was added and dissolved in eth-
anol using corresponding concentrations of ethanol as con-
trols, whereas prednisolone phosphate was added in the
Hepes/NaCl buffer. Cell viability was determined after 24, 48,
and 72 hours of incubation by XTT assay (Sigma) according
to the manufacturer’s instructions.
Histology
C26 and B16.F10 tumor-bearing mice received a single
intravenous injection of either free or liposomal 20 mg/kg
prednisolone phosphate when tumor volume reached
20 mm3. Tumors were dissected 72 hours after injection.
Tumors were fixed with liquid nitrogen for immunohistochem-
ical staining and with 2% glutaraldehyde for toluidin blue
staining. Five-micrometer slides were cut. Sections from
frozen tissues were fixed in acetone and air-dried for immu-
nohistochemical analysis [17]. Rat anti–mouse CD31 anti-
body (BD Pharmingen, Heidelberg, Germany) was used as
a primary antibody and incubated for 45 minutes at room
temperature. After washing three times with PBS supple-
mented with 5% fetal calf serum, endogenous peroxidase
activity was inhibited by incubating with 0.075% H2O2 for
20 minutes. As a secondary antibody, rabbit anti–rat HRP
(DAKO A/S, Glostrup, Denmark) was used with 2% normal
mouse serum. Sections were incubated for 45 minutes at
room temperature and washed three times with PBS with
5% fetal calf serum. After incubation with the tertiary anti-
body, goat anti–rabbit HRP (DAKO A/S) with 2% normal
mouse serum (for 30 minutes and washing three times)
was stained with peroxidase substrate 3-amino, 9-ethyl-
carbazole. Slides were counterstained in hematoxylin
(Sigma-Aldrich Co.) and mounted in Kaiser’s glycerol gelatin
(Merck, Darmstadt, Germany).
Glutaraldehyde fixed sections were dehydrated and em-
bedded in glycol methacrylate. Slides were stained with
toluidin blue (Fluka, Zwijndrecht, The Netherlands).
All slides were evaluated by light microscopy regarding
tumor tissue density, location, number and structure of
blood vessels, presence of hemorrhagic areas, and pres-
ence, size, and location of picnotic/necrotic areas. These
observations were related to the cellular localization of
liposomes in tumor tissues. For this purpose, liposomes
were labeled with colloidal gold. Twenty-four hours after
injection of the liposomes, tumors were dissected and
snap-frozen in liquid nitrogen, and 5-mm slides were cut.
Slides were evaluated by light microscopy after silver
enhancement of the colloidal gold and hematoxylin/eosin
staining. For transmission electron microscopy, tumor tis-
sue was fixed in 2% glutaraldehyde in PBS, postfixed in
2% glutaraldehyde/0.1 M sodium cacodylate followed by
2% OsO4/0.1 M sodium cacodylate, stained with uranyl
acetate, dehydrated in acetone, and embedded in Durcu-
pan plastic. Seventy- to 90-nm sections were cut, collected
on copper G200 grids, and examined at an accelerating
voltage of 60 kV in a Philips EM 201 transmission electron
microscope (Philips Analytical Electron Optics, Eindhoven,
The Netherlands).
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Statistical Analyses
Data were analyzed by one-way ANOVA with Dunnett’s
posttest using GraphPad InStat version 3.05 for Windows,
GraphPad Software (San Diego, CA). Data were logarithmi-
cally transformed to correct for significant differences be-
tween the SD values of groups, when appropriate, according
to Bartlett’s test. Spearman’s rank correlation coefficient was
calculated to identify dose response.
Results
Tissue Distribution of 111In-Labeled Liposomes
Figure 1 presents the tissue distribution data of the 111In-
labeled liposomes at 6 and 24 hours after intravenous
injection in C26 or B16.F10 tumor-bearing mice. Approxi-
mately 60% of the injected dose (ID) was still present in
the circulation at 6 hours after administration in both tumor
models, whereas 15% ID was still circulating at 24 hours
postinjection. These values correspond to previous data on
the circulation kinetics of liposomes [10]. Seven to 10% ID
could be recovered from tumor tissues in both the C26 and
B16.F10 models at 24 hours after injection, which was about
two-fold higher than the levels at 6 hours postinjection. At
both time points, approximately the same amount was
present in the livers of both strains of tumor-bearing mice.
Relatively low amounts of 111In-labeled liposomes were
recovered from the spleen, kidney, and lung in both mouse
models at 6 and 24 hours after injection.
Antitumor Activity of Liposomal Prednisolone Phosphate
Versus Free Prednisolone Phosphate: Single Dose–
Response Relationship
To compare the effects of different doses of liposomal
prednisolone phosphate and free prednisolone phosphate
on tumor growth, B16.F10 or C26 tumor-bearing mice re-
ceived a single injection of either formulation at the moment
that the tumor became palpable. At 1 week after injection,
tumor volumes were smaller with increasing doses of lipo-
somal prednisolone phosphate in both mouse models, as
shown in Figure 2 (B16: Spearman correlation coefficient
r = 0.92, P < .001; C26 Spearman correlation coefficient
r = 0.82, P < .01). These correlation coefficients indicate a
positive correlation between the dose of liposomal prednis-
olone phosphate and antitumor effects. Prednisolone phos-
phate, 20 mg/kg, was the maximum dose of the liposomal
formulation that could be administered in view of the maximal
injection volume. Treatment of B16.F10 and C26 tumor-
bearing mice with 20 or 50 mg/kg free prednisolone phos-
phate did not significantly affect tumor volumes compared
to vehicle-treated control animals (Figure 2).
Dependence of Antitumor Effect on Treatment Schedule
To determine if (and to what extent) the antitumor effects
depended on the treatment schedule, liposomal and free
prednisolone phosphate were injected at a dose of 20 mg/kg
on days 1, 7, and 14, or as a single dose of 20 mg/kg on day
7 or 14 after tumor cell inoculation. The results are shown
in Figure 3.
B16 model The tumor volumes of B16.F10 tumor-bearing
mice that received treatment on days 1, 7, and 14 are shown
in Figure 3A. Tumors became palpable on day 7 in all
treatment groups, indicating that none of the treatments
delayed tumor growth between days 1 and 7. A second dose
of liposomal prednisolone phosphate on day 7, however,
resulted in 92 ± 10% tumor growth inhibition between days 7
and 14 compared to controls (P < .05), whereas free pred-
nisolone phosphate did not affect tumor volume. On day 14,
mice received a third injection. On day 17, the average tumor
volume in the liposomal prednisolone phosphate–treated
group was 79 ± 26% smaller (P < .01) than the tumor volume
in the mice receiving free prednisolone phosphate and
vehicle. At this time point, the experiment was ended as
4 of 10 mice from the latter two groups had large tumor
sizes (>2 cm3).
After a single injection of liposomal or free prednisolone
phosphate on day 7, a significantly smaller tumor volume
was only seen after treatment with liposomal prednisolone
phosphate, with average inhibition of tumor growth of 89 ±
24% on day 14 and 67 ± 27% on day 17 compared to controls
(P < .05, both time points) (Figure 3C). Furthermore, even a
single injection of liposomal prednisolone phosphate on day
14 produced 58 ± 31% tumor growth inhibition on day 17
compared to controls (P < .05) (Figure 3E ).
C26 model C26-bearing mice received the first injection on
day 1 and a second on day 7 after tumor cell inoculation. As
tumors in all treatment groups became palpable around day
10, the effect on tumor growth of the first injections appeared
to beminimal, although tumor volume was 89 ± 9% smaller in
liposomal prednisolone phosphate–treated animals than in
controls on day 14. On day 21, 1 week after the third dose on
day 14, average tumor volume in liposomal prednisolone
phosphate–treated animals was 89 ± 10% smaller than that
in controls (P < .01) (Figure 3B ).
Although a single dose of liposomal prednisolone phos-
phate on day 7 resulted in 66 ± 32% tumor growth inhibi-
tion on day 14 and 67 ± 33% inhibition on day 21, these
Figure 1. Tissue distribution of 25 mol/kg lipid. 111In-labeled liposomes at
6 and 24 hours after intravenous administration in B16.F10 tumor-bearing
C57Bl/6 mice or C26 tumor-bearing Balb/c mice. Mean ± SD; n = 5 animals
per experimental group.
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differences were not statistically significant compared to
the control and free drug–treated groups (Figure 3D ). A sin-
gle injection of liposomal prednisolone phosphate on day
14 resulted in 78 ± 19% tumor growth inhibition (P < .05)
(Figure 3F ).
These results indicate that liposomal prednisolone phos-
phate can effectuate strong antitumor effects, provided
that a palpable tumor mass is present at the time of in-
jection. Likely, the degree of liposomal tumor localization is
minimal in small—not yet palpable—tumors as vascular
Figure 2. Effects of liposomal (left) and free prednisolone phosphate (right) on tumor growth in B16.F10 or C26 tumor-bearing mice. Mice received a single
injection of the indicated dose and formulation of prednisolone phosphate on the day that the tumors became palpable. Tumor volume after 1 week is reported.
Mean ± SD; n = 5 animals per experimental group.
Figure 3. Effects of different treatment schedules of free and liposomal prednisolone phosphate on tumor growth. The formulations were injected at a dose of
20 mg/kg on days 1, 7, and 14 (A and B), or as a single injection on day 7 (C and D) or day 14 (E and F) in B16.F10 tumor-bearing mice (A, C, and E) or C26 tumor-
bearing mice (B, D, and F). Mean ± SD; n = 5 animals per experimental group.
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integrity is hardly compromised in this time frame and,
consequently, the enhanced permeability and retention
effect are absent. These results would also suggest that
local accumulation of liposomes is critically important for
therapeutic efficacy.
Importance of the Long-Circulation Property of Liposomes
for Tumor Growth Inhibition
As circulation time of liposomes is positively correlated to
target site accumulation [10–14], liposomal circulation time
may be a critical factor for achieving antitumor efficacy.
We evaluated a prednisolone phosphate–containing short-
circulating liposome type and compared the antitumor
activity of this formulation to long-circulation liposomal pred-
nisolone phosphate in C26 tumor-bearing mice. Both formu-
lations were injected on day 14 after tumor cell inoculation,
as the previous experiment showed the lowest variation in
effects of a single injection of long-circulating liposomal
prednisolone phosphate in this model at this time point. The
tumor volume of short-circulating liposomes-encapsulated
prednisolone phosphate– treated animals was not signi-
ficantly different from saline-treated animals, whereas ani-
mals treated with liposomes-encapsulated prednisolone
phosphate experienced a significantly reduced tumor growth
rate, with tumor volume being 71 ± 7% smaller compared to
vehicle-treated animals (P < .05) (Figure 4). These results
indicate that the long-circulating property is important for
the antitumor effect. As liposomal circulation time is posi-
tively correlated to liposome accumulation in the tumor,
these results imply the importance of liposomal tumor lo-
calization for antitumor efficacy, while making a possible
(immunosuppressive) effect brought about peripherally less
likely to be the main determinant.
Effects of Prednisolone on HUVEC, B16.F10, or C26
Proliferation In Vitro
To evaluate whether the antitumor effect was due to a
direct cytotoxic effect of prednisolone or prednisolone phos-
phate, HUVEC, B16.F10, and C26 cells were incubated
in vitro for 24, 48, and 72 hours with increasing concentra-
tions of prednisolone or prednisolone phosphate ranging
from 1 ng/ml to 100 mg/ml. No decrease in cell viability was
noted up to the maximum concentrations tested for C26 and
HUVEC (data not shown). Only B16.F10 cells showed a
modest inhibition of proliferation at the highest concentration
of 100 mg/ml prednisolone after incubation for 48 or 72 hours
with apparent reductions in proliferation of 21 ± 3% and
41 ± 2% (mean ± SD of three measurements), respectively,
compared to vehicle-treated control cells. Prednisolone
phosphate did not affect cell proliferation at any of the
concentrations tested.
To relate these modest effects to drug levels in the tumor
tissues, prednisolone and prednisolone phosphate levels at
24 hours after intravenous injection of liposomal predniso-
lone phosphate or free prednisolone phosphate were deter-
mined by high-performance liquid chromatography analysis.
At this time point, total prednisolone (phosphate) levels in the
tumor tissue were undetectable after injection of free pred-
nisolone phosphate (n = 3–4). For the liposomal formulation,
total prednisolone (phosphate) concentrations of 10 ± 1 mg/g
in C26 tumor tissues and 19 ± 6 mg/g in B16.F10 tumor
tissues were measured (n = 3–4 mean ± SD), which is
approximately 2% to 5% ID. These concentrations would
make a direct effect of liposomal prednisolone on tumor cell
proliferation unlikely. However, these concentrations repre-
sent overall tumor levels and do not account for temporary
regional peak concentrations. Intratumoral distribution of
colloidal gold-labeled liposomes at 24 hours after injection
shows that there are large regional variations in degrees of
liposome localization, with liposomes being mainly observed
in the immediate vicinity of blood vessels in both tumor
models (Figure 5, A and B). Within these areas, liposomes
are predominantly taken up by macrophages and recovered
in endosomal compartments (Figure 5, C and D). It is
conceivable that the high concentrations in these specific
areas could have diverse pharmacologic effects on different
cell types.
Histologic Examination of Tumor Tissue
To evaluate the effects of treatment on tumor histology,
we compared toluidin blue and CD31-stained sections of
B16.F10 and C26 tumor tissues from liposomal prednisolone
phosphate– treated and untreated mice. Treatment was
initiated when the tumors became palpable and tumors were
evaluated 3 days after treatment as this was the time frame
in which pronounced neovascularization occurred. It is
thought that inhibition of this neovascularization forms the
basis of the antitumor effects of glucocorticoids. Tumor
sections were evaluated regarding tumor cell density, loca-
tion, number, and structure of blood vessels to assess
possible changes related to angiogenesis; the presence of
hemorrhagic areas to determine the vascular integrity of
capillaries; and the presence, size, and location of picnotic/
necrotic cell areas to investigate tumor viability (Table 1).
The most striking observation in the antitumor expe-
riments was that tumors from liposomal prednisolone
Figure 4. Effects of short-circulating and long-circulating prednisolone
phosphate liposomes on C26 tumor growth. Tumor-bearing mice received
a single injection of 20 mg/kg of the indicated formulations of prednisolone
phosphate on day 14 after tumor cell inoculation. Mean ± SD; n = 5 animals
per experimental group.
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phosphate–treated mice had a size that was comparable to
the tumor size at the start of treatment, whereas control
tumors showed a sharp increase in tumor volume. Despite
this pronounced difference in tumor size, tumor morphology
was remarkably similar. More specifically, liposomal prednis-
olone phosphate appeared to have no influence on the
increase in tumor vascularization in both tumor models, the
increase in tumor cell density inC26 tumors, or the increase in
a number of hemorrhagic areas in B16.F10 tumors that were
observed in control or free prednisolone phosphate–treated
animals within this time frame. Apparently, liposomal pred-
nisolone phosphate does not affect tumor ‘‘maturation’’’
despite a strong inhibition of tumor growth rate.
The only notable difference was that in all of the liposomal
prednisolone phosphate–treated tumors, areas of picnotic/
necrotic cells in the center of the tumor could be observed.
These patterns were not observed in free prednisolone
phosphate– or vehicle–treated controls (Table 1, Figure 6).
Although we did not directly assess the functionality of
blood vessels in this area, the vessels seemed perfused
as indicated by the presence of erythrocytes. Therefore,
necrosis in these areas did not seem to be the result of lack
of vascularization.
Discussion
The present study demonstrates for the first time that
liposome-encapsulated glucocorticoids exert strong tumor
growth– inhibiting effects in vivo. Antitumor effects were
observed when liposomal prednisolone phosphate was ad-
ministered in a low-frequency (single dose or weekly) dosing
schedule and at substantially lower doses than required for
free glucocorticoids [5–7,9].
Liposomes have previously been used to increase the
delivery of a variety of drugs to tumor tissues [18–20].
Probably, the best-known formulation in this respect is
liposome-encapsulated doxorubicin, marketed as Doxil or
Caelyx [19]. The long-circulating property of these formula-
tions allows liposomes to extravasate as a result of the
enhanced vascular permeability in solid tumor tissues, lead-
ing to selective accumulation at the site of malignancy
Figure 5. Intratumoral distribution of liposomes. Colloidal gold-labeled liposomes were intravenously injected in C26 tumor-bearing (A) or B16.F10 tumor-bearing
(B) mice. Vascular lumina are indicated by an asterisk (A and B; bar = 25 m). Macrophages that are filled with silver-enhanced colloidal gold and are located close
to the tumor blood vessels can be visualized. Transmission electron microscopy images confirm that these cells are macrophages (C) (n = nucleus; c = collagen;
e = endosome; bar = 2 m) and show that the colloidal gold particles are present in endosomal vesicles (D) (bar = 600 nm).
Table 1. Effect of Treatment with Liposomal Prednisolone Phosphate, Free
Prednisolone Phosphate, or Vehicle on Tumor Size and Tumor Histology.
C26 B16.F10
Start End Start End
C F L C F L
Tumor size (mm 3 ) 16 59 48 15 14 163 136 17
Blood vessels  + + +  + + +
Hemorrhagic area      ± ± ±
Necrosis    +*  ±y ±y +*
High cell density  + + + ++ ++ ++ ++
Tumor tissue was excised from C26 or B16.F10 tumor-bearing mice at the
start oftreatment or 3 days after a single intravenous injection with liposomal
prednisolonephosphate (L), or free prednisolone phosphate (F) at a dose of
20 mg/kg, or vehicle (C). Tissue slides were evaluated regarding vascula-
rization (CD31 staining), tumorcell density, and occurrence of necrosis and
hemorrhagic areas (toluidine bluestaining).
Slides were scored as: () (nearly) absent; (+) present; (++) strongly present.
*Predominantly in tumor core.
y Infrequently observed without preferential localization.
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[18–20]. Indeed, in both the B16.F10 and C26 tumor
models used in this study, 7% to 10% of the ID of liposomes
localized in the tumor at 24 hours after injection, which is
similar to previously reported data [10,18–20]. At this time
point, approximately 15% of the ID was still circulating in the
blood stream, which is consistent with a long-circulatory
behavior.
Furthermore, liposome encapsulation increased the lev-
els of the drug in the tumor at 24 hours after injection
compared to administration of the free drug. When adminis-
tered in free form, no prednisolone (phosphate) could be
detected in the tumor tissues, whereas administration of
the liposomal form resulted in 2% to 5% ID of prednisolone
in the tumor tissue. The fact that this percentage is substan-
tially lower than the 7% to 10% ID of (radioactively labeled)
liposomes that accumulate at the site of the malignancy is
likely to be explained by intratumoral conversion of prednis-
olone phosphate to prednisolone. This subsequently leads
to a redistribution of the drug over the body as predniso-
lone easily passes membranes.
Administration of liposome-encapsulated prednisolone
phosphate resulted in a dose-dependent antitumor effect in
both the B16.F10 and C26 subcutaneous tumor models. In
both tumor models, the maximum dose of 20 mg/kg (deter-
mined by the maximal injection volume) resulted in approx-
imately 90% tumor inhibition over a 1-week period when
administered as a single dose at the moment that the tumor
became palpable. In contrast, free prednisolone phosphate
did not affect tumor growth even at a dose of 50 mg/kg.
The in vitro studies indicate that the underlying mecha-
nism of tumor growth inhibition is probably not related to a
direct inhibition of tumor cell proliferation. Several other
studies have also shown that the pharmacologic effect of
glucocorticoids does not occur through a direct action on
tumor cells, but is mediated by interference with the tumor
neovascularization [21–25]. However, we also did not ob-
serve an effect of prednisolone phosphate or prednisolone
on the proliferation of HUVEC. This indicates that a direct
effect on proliferating endothelial cells is absent. Neverthe-
less, other angiogenesis-driving processes such as produc-
tion and/or release of proangiogenic and antiangiogenic
factors [24,25] may still be affected in vivo by the prolonged
exposure to high levels of the drug. The preferential
localization of liposomes in the immediate vicinity of tumor
neovasculature may cause extremely high local drug levels,
which can mediate such effects. In addition, the hypothesis
that inflammatory processes in and around the tumor are
important in the angiogenic cascade could mean that gluco-
corticoids’ immunosuppressive action may also be of rele-
vance in this respect [26,27]. It has also been suggested that
tumor-associated macrophages may secrete mitogens,
growth factors, and enzymes that stimulate both tumor cell
survival and growth as well as angiogenesis. In this view,
liposomal prednisolone phosphate may disturb the symbiotic
relationship between tumor cells and macrophages [28].
The observations of strong macrophage uptake of liposomes
in the tumor tissue may support this theory. Additional
research is required to address these issues in detail.
Microscopic analysis of tumor tissues indicated that treat-
ment with liposomal prednisolone phosphate has pro-
nounced effects on tumor size and produced necrotic
areas in the core of the tumor, but overall has remarkably
limited effects on tumor morphology. Liposomal treatment
did not affect the increase in tumor vascularization seen in
Figure 6. Effect of single liposomal prednisolone phosphate treatment on the morphology of tumor tissues and blood vessel density. Liposome-treated tumors
showed similar blood vessel density as vehicle-treated control tumors (upper panels), a pattern resembling that observed for free prednisolone phosphate– treated
tumors (not shown). In all liposome-treated tumors, areas of necrosis in the core of the tumor were observed, which were absent in vehicle-treated (lower panels)
and free prednisolone phosphate– treated tumors (not shown). Similar observations were made in B16.F10 tumor-bearing mice (not shown).
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both models, nor the increase in tumor cell density in C26
tumors, nor the increase in the number of hemorrhagic areas
in B16.F10 tumors. These observations do not exclude or
support an antiangiogenic mechanism of action. In previous
studies with angiogenesis inhibitors, it was shown that tumor
vessels may grow or remain viable during antiangiogenic
treatment. The absolute number of blood vessels, however,
determines the number of tumor cells that can be supported,
thereby dictating tumor volume without an apparent reduc-
tion in tumor blood vessel density [29]. Future studies
investigating the effects of liposomal prednisolone phos-
phate on the molecular level should result in a clearer
understanding of the precise mechanism of action of
our formulation.
Regardless of the proposed underlying mechanism, vari-
ous studies have reported a concentration-dependent inhi-
bition of the angiogenic process by glucocorticoids [21–25].
This concentration dependency is further illustrated by a
study in rats demonstrating that local administration of
glucocorticoids in sponge implants, which act as a slow-
release vehicle, was more effective in inhibiting angio-
genesis than systemic treatment [30]. Also in our study, the
importance of prolonged high local drug levels is supported
by the observation that the same dose of liposomal prednis-
olone phosphate in short-circulating liposomes did not
inhibit tumor growth. Short-circulating liposomes were
formed by omitting the poly(ethylene glycol)–conjugated
lipid. Exchanging this lipid for phosphatidylglycerol intro-
duced a negative charge on the liposome surface, which
promotes macrophage uptake and thereby reduces circu-
lation time of the short-circulating liposomes even fur-
ther [13]. These short-circulating liposomes are rapidly
taken up by macrophages mainly in the liver and spleen,
and are therefore unable to accumulate at the tumor. The
limited localization of short-circulating liposomes in the tumor
was paralleled by a decrease in activity, again indicating that
local high levels of glucocorticoids in tumors are pivotal for
antitumor effects.
In conclusion, the present study shows for the first time
that liposome-encapsulated prednisolone phosphate exerts
potentantitumoreffectswhenadministered ina low-frequency
dosing schedule. The liposomal formulation caused high
intratumoral levels of prednisolone phosphate for a pro-
longed period of time. The advantage of the current system
for future clinical use is the relatively low-dose and low-
frequency schedule with which prednisolone phosphate
can be administered to induce antitumor efficacy. Further-
more, the use of glucocorticoids may reduce toxicity in
combination therapy as they have a different side effects
profile than the traditional oncolytics. Future studies will
focus on the molecular effects of liposomal prednisolone
phosphate treatment on the various stages of neovasculari-
zation representative of clinical conditions.
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